

Richard A Becker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11828000/publications.pdf>

Version: 2024-02-01

53
papers

1,819
citations

236925

25
h-index

276875

41
g-index

54
all docs

54
docs citations

54
times ranked

1866
citing authors

#	ARTICLE	IF	CITATIONS
1	Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium. <i>Toxicological Sciences</i> , 2022, 188, 143-152.	3.1	17
2	The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay. <i>Toxicology and Applied Pharmacology</i> , 2020, 387, 114774.	2.8	10
3	Recommendations for further revisions to improve the International Agency for Research on Cancer (IARC) Monograph program. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 113, 104639.	2.7	13
4	Internal Threshold of Toxicological Concern (iTTC): Where We Are Today and What Is Possible in the Near Future. <i>Frontiers in Toxicology</i> , 2020, 2, 621541.	3.1	5
5	Toward the Development and Application of an Environmental Risk Assessment Framework for Microplastic. <i>Environmental Toxicology and Chemistry</i> , 2019, 38, 2087-2100.	4.3	69
6	Transforming regulatory safety evaluations using New Approach Methodologies: A perspective of an industrial toxicologist. <i>Current Opinion in Toxicology</i> , 2019, 15, 93-98.	5.0	2
7	The Predictive Analytics Toolkit (PAT): User-friendly predictive analytics for advancing new approach methodologies (NAMs). <i>Computational Toxicology</i> , 2019, 12, 100107.	3.3	0
8	Developing context appropriate toxicity testing approaches using new alternative methods (NAMs). <i>ALTEX: Alternatives To Animal Experimentation</i> , 2019, 36, 532-534.	1.5	30
9	Development of an adverse outcome pathway for chemically induced hepatocellular carcinoma: case study of AFB1, a human carcinogen with a mutagenic mode of action. <i>Critical Reviews in Toxicology</i> , 2018, 48, 312-337.	3.9	23
10	Utilizing Threshold of Toxicological Concern (TTC) with high throughput exposure predictions (HTE) as a risk-based prioritization approach for thousands of chemicals. <i>Computational Toxicology</i> , 2018, 7, 58-67.	3.3	53
11	Quantitative weight of evidence to assess confidence in potential modes of action. <i>Regulatory Toxicology and Pharmacology</i> , 2017, 86, 205-220.	2.7	50
12	FutureTox III: Bridges for Translation. <i>Toxicological Sciences</i> , 2017, 155, 22-31.	3.1	22
13	How well can carcinogenicity be predicted by high throughput "characteristics of carcinogens" mechanistic data?. <i>Regulatory Toxicology and Pharmacology</i> , 2017, 90, 185-196.	2.7	37
14	Does GLP enhance the quality of toxicological evidence for regulatory decisions?: TABLE 1.. <i>Toxicological Sciences</i> , 2016, 151, 206-213.	3.1	17
15	Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review. <i>Environment International</i> , 2016, 92-93, 630-646.	10.0	58
16	Approaches for describing and communicating overall uncertainty in toxicity characterizations: U.S. Environmental Protection Agency's Integrated Risk Information System (IRIS) as a case study. <i>Environment International</i> , 2016, 89-90, 110-128.	10.0	27
17	How well can in vitro data predict in vivo effects of chemicals? Rodent carcinogenicity as a case study. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 77, 54-64.	2.7	16
18	Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 72, 514-537.	2.7	198

#	ARTICLE	IF	CITATIONS
19	An exposure:activity profiling method for interpreting high-throughput screening data for estrogenic activity—Proof of concept. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 71, 398-408.	2.7	45
20	Challenges in using the ToxRefDB as a resource for toxicity prediction modeling. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 72, 610-614.	2.7	8
21	Modernizing problem formulation for risk assessment necessitates articulation of mode of action. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 72, 538-551.	2.7	19
22	Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 71, 463-477.	2.7	87
23	The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 73, 172-190.	2.7	42
24	Instruments for Assessing Risk of Bias and Other Methodological Criteria of Animal Studies: Omission of Well-Established Methods. <i>Environmental Health Perspectives</i> , 2014, 122, A66-7.	6.0	1
25	Relevance Weighting of Tier 1 Endocrine Screening Endpoints by Rank Order. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2014, 101, 90-113.	1.4	36
26	Interpreting Estrogen Screening Assays in the Context of Potency and Human Exposure Relative to Natural Exposures to Phytoestrogens. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2014, 101, 114-124.	1.4	6
27	Developing scientific confidence in HTS-derived prediction models: Lessons learned from an endocrine case study. <i>Regulatory Toxicology and Pharmacology</i> , 2014, 69, 443-450.	2.7	27
28	Lessons learned, challenges, and opportunities: The U.S. Endocrine Disruptor Screening Program. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2014, 31, 63-78.	1.5	22
29	Read-across approaches - misconceptions, promises and challenges ahead. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2014, 31, 387-396.	1.5	90
30	Use and validation of HT/HC assays to support 21st century toxicity evaluations. <i>Regulatory Toxicology and Pharmacology</i> , 2013, 65, 259-268.	2.7	35
31	Advancing human health risk assessment: Integrating recent advisory committee recommendations. <i>Critical Reviews in Toxicology</i> , 2013, 43, 467-492.	3.9	42
32	A survey of frameworks for best practices in weight-of-evidence analyses. <i>Critical Reviews in Toxicology</i> , 2013, 43, 753-784.	3.9	83
33	Evidence-based toxicology for the 21st century: Opportunities and challenges. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2013, 30, 74-104.	1.5	42
34	Interlaboratory Study Comparison of the 15-Day Intact Adult Male Rat Screening Assay: Evaluation of an Antithyroid Chemical and a Negative Control Chemical. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2012, 95, 63-78.	1.4	1
35	Development of Screening Tools for the Interpretation of Chemical Biomonitoring Data. <i>Journal of Toxicology</i> , 2012, 2012, 1-10.	3.0	11
36	Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 59, 397-411.	2.7	58

#	ARTICLE	IF	CITATIONS
37	Assessment of margin of exposure based on biomarkers in blood: An exploratory analysis. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 61, 44-52.	2.7	9
38	Hypothesis-driven weight of evidence framework for evaluating data within the US EPA's Endocrine Disruptor Screening Program. <i>Regulatory Toxicology and Pharmacology</i> , 2011, 61, 185-191.	2.7	58
39	Chemical Safety Studies: Conrad and Becker Respond. <i>Environmental Health Perspectives</i> , 2011, 119, .	6.0	5
40	Enhancing Credibility of Chemical Safety Studies: Emerging Consensus on Key Assessment Criteria. <i>Environmental Health Perspectives</i> , 2011, 119, 757-764.	6.0	26
41	An enhanced tiered toxicity testing framework with triggers for assessing hazards and risks of commodity chemicals. <i>Regulatory Toxicology and Pharmacology</i> , 2010, 58, 382-394.	2.7	15
42	Good Laboratory Practices: Becker et al. Respond. <i>Environmental Health Perspectives</i> , 2010, 118, .	6.0	4
43	Good Laboratory Practices and Safety Assessments. <i>Environmental Health Perspectives</i> , 2009, 117, A482-3; author reply A483-4.	6.0	29
44	Toxicity Testing in the 21st Century: A View from the Chemical Industry. <i>Toxicological Sciences</i> , 2009, 112, 297-302.	3.1	48
45	Results of the negative control chemical allyl alcohol in the 15-day intact adult male rat screening assay for endocrine activity. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2008, 83, 117-122.	1.4	6
46	Does The Standard Toxicological Testing Paradigm for Industrial Chemicals Apply to Screening for Children's Health Risks?. <i>The Open Toxicology Journal</i> , 2008, 2, 42-60.	1.0	1
47	Tiered toxicity testing: Evaluation of toxicity-based decision triggers for human health hazard characterization. <i>Food and Chemical Toxicology</i> , 2007, 45, 2454-2469.	3.6	20
48	Report of an ISRTP Workshop: Progress and barriers to incorporating alternative toxicological methods in the U.S.. <i>Regulatory Toxicology and Pharmacology</i> , 2006, 46, 18-22.	2.7	24
49	Alternative methods of selecting rat hepatocellular noduli resistant to 2-acetylaminofluorene. <i>International Journal of Cancer</i> , 1987, 40, 643-645.	5.1	93
50	A summary of the results of 55 chemicals screened for developmental toxicity in mice. <i>Teratogenesis, Carcinogenesis, and Mutagenesis</i> , 1987, 7, 17-28.	0.8	35
51	Overview and summary: Workshop on the Chernoff/Kavlock preliminary developmental toxicity test. <i>Teratogenesis, Carcinogenesis, and Mutagenesis</i> , 1987, 7, 119-127.	0.8	14
52	Validation of an in vivo developmental toxicity screen in the mouse. <i>Teratogenesis, Carcinogenesis, and Mutagenesis</i> , 1986, 6, 361-374.	0.8	54
53	Methylation of liver DNA guanine in hydrazine hepatotoxicity: dose-response and kinetic characteristics of O6-methylguanine and formation and persistence in rats. <i>Carcinogenesis</i> , 1981, 2, 1181-1188.	2.8	67